Wright, Doug

Nicole Martin is a technology specialist at WilmerHale. She joined the firm in 2005.

Practice

Dr. Martin's practice includes the preparation and prosecution of biotechnology and pharmaceutical patents and assisting in intellectual property litigation.

Prior to joining the firm, Dr. Martin's thesis research focused on identifying genes involved in breast cancer and mammary gland development. Her technical background includes molecular and cell biology, transgenic mouse models, mammary gland transplantation studies, RNA interference (RNAi) and DNA microarrays.

Dr. Martin has presented her work at many seminars and conferences and has received numerous awards. She has worked extensively in biotechnology and pharmaceutical research in Canada. She has been a research assistant at Glaxo Wellcome Inc., Biochem Therapeutic Inc., Glaxo Canada Inc. and Allelix Biopharmaceuticals Inc., where she participated in both basic research and formulation development.

Speaking Engagements

• Stem Cell Genomics Meeting: Canadian Stem Cell Network – Ottawa Health Research Institute – Ottawa, Canada – 2004
• AACR 94th Annual Meeting: Minisymposium on 'The Malignant Phenotype' – Washington, DC – 2003
• Gordon Research Conference: Cancer: Mechanisms and Models – Salve Regina University – Newport, RI – 2001
• Wnt Signaling Meeting – Stanford University – Palo Alto, CA – 1999

Publications

• Martin, Nicole L., "Engrailed genes in mammary gland development and breast tumorigenesis," Doctoral Dissertation, Université de Montréal (2006).
• Martin, Nicole L. and Guy Sauvageau, "En-1 deficiency leads to abnormal ductal development in the mouse mammary gland," Submitted, Developmental Dynamics (2006).
• Martin, N.L., Saba-El-Leil, M.K., Sadekova, S., Meloche, S. and Sauvageau, G., "EN2 is a candidate oncogene in human breast cancer," Oncogene 24(46): 6890-6901 (2005).
• Sauvageau, G., Martin, N.L., Meloche, S. and Saba-El-Leil, M.K., "EN2 Gene, Diagnostic and Therapeutic Uses Thereof," Patent Pending before the USPTO and the CIPO.